XML 44 R35.htm IDEA: XBRL DOCUMENT v3.23.3
Collaboration Agreements, License Agreement and Revenues - Astellas Agreements - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended
Apr. 30, 2006
Jun. 30, 2005
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Total revenue     $ 40,134,000     $ 15,735,000     $ 120,614,000 $ 106,367,000  
Deferred Revenue     7,325,000           7,325,000   $ 12,739,000
Drug Product Revenue, Net [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Total revenue     1,320,000     $ (4,077,000)     17,701,000 $ 4,610,000  
Japan [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Transaction price, variable consideration from estimated future co-development billing                 0    
Japan [Member] | Drug Product Revenue, Net [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Total revenue       $ 14,400,000 $ 1,700,000   $ 9,800,000        
Astellas Agreement [Member] | Japan [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Upfront, non-contingent and time-based payments received   $ 172,600,000                  
Additional consideration based on net sales description               the low 20% range of the list price      
Aggregate consideration received excluding drug product revenue     105,100,000           $ 105,100,000    
Changes in revenue from changes to estimated variable consideration     0                
Astellas Agreement [Member] | Europe [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Upfront, non-contingent and time-based payments received $ 745,000,000                    
Additional consideration based on net sales description                 low 20% range    
Aggregate consideration received excluding drug product revenue     685,000,000           $ 685,000,000    
Transaction price, variable consideration from estimated future co-development billing                 $ 800,000    
Percentage of joint development costs committed to fund 50.00%                    
Transaction price and allocated to performance obligations             $ 25,000,000        
Changes in revenue from changes to estimated variable consideration     $ 0